This study focuses on pediatric low-grade glioma, a type of brain tumor that occurs in children and young people under 25 years of age. The study specifically looks at cases where the tumor has certain genetic changes called RAF alterations and requires treatment for the first time. The purpose is to compare two different treatment approaches: a new medication called tovorafenib versus standard chemotherapy treatments that include vincristine, vinblastine, and carboplatin.

The study will determine which treatment is more effective at shrinking or controlling the tumor. Patients will be randomly assigned to receive either tovorafenib tablets or oral suspension taken by mouth, or standard chemotherapy medications given through an intravenous line (a small tube inserted into a vein). The study will measure how well tumors respond to treatment and how long patients remain free from tumor growth.

Doctors will regularly monitor patients using brain scans and medical examinations to track the tumor’s response to treatment. The study will continue for several years to gather long-term information about how well each treatment works and how it affects patients’ health over time. This research aims to help determine the most effective treatment option for children and young people with this specific type of brain tumor.